MA51878A - AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS - Google Patents

AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS

Info

Publication number
MA51878A
MA51878A MA051878A MA51878A MA51878A MA 51878 A MA51878 A MA 51878A MA 051878 A MA051878 A MA 051878A MA 51878 A MA51878 A MA 51878A MA 51878 A MA51878 A MA 51878A
Authority
MA
Morocco
Prior art keywords
kit inhibitors
aminothiazole compounds
aminothiazole
compounds
inhibitors
Prior art date
Application number
MA051878A
Other languages
French (fr)
Inventor
Nicholas E Bencivenga
David C Dalgarno
Joseph M Gozgit
Wei-Sheng Huang
Anna Kohlmann
Feng Li
Jiwei Qi
William C Shakespeare
Ranny M Thomas
Yihan Wang
Xiaotian Zhu
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MA51878A publication Critical patent/MA51878A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
MA051878A 2016-12-15 2017-12-14 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS MA51878A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662434845P 2016-12-15 2016-12-15

Publications (1)

Publication Number Publication Date
MA51878A true MA51878A (en) 2020-12-30

Family

ID=60957442

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051878A MA51878A (en) 2016-12-15 2017-12-14 AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS

Country Status (13)

Country Link
US (2) US11001580B2 (en)
EP (1) EP3555090A1 (en)
JP (2) JP7158382B2 (en)
KR (1) KR102594476B1 (en)
CN (3) CN110291086B (en)
AU (2) AU2017376624B2 (en)
BR (1) BR112019012239A2 (en)
CA (1) CA3047106A1 (en)
EA (1) EA201991198A1 (en)
IL (2) IL267262B (en)
MA (1) MA51878A (en)
MX (2) MX2019007079A (en)
WO (1) WO2018112136A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291086B (en) 2016-12-15 2023-08-11 阿瑞雅德制药公司 Aminothiazole compounds as C-KIT inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022009947A (en) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof.
KR102535840B1 (en) * 2020-07-31 2023-05-23 (주)파로스아이바이오 Use of 2,3,5-Substituted Thiophene Compound for Prevention, Improvement or Treatment of Gastrointestinal Stromal Tumor
EP4274830A1 (en) * 2021-01-06 2023-11-15 Theseus Pharmaceuticals, Inc. Aminothiazole compounds as c-kit inhibitors
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
WO2023050007A1 (en) * 2021-09-29 2023-04-06 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024069592A1 (en) * 2022-09-29 2024-04-04 Repare Therapeutics Inc. N-(5-substituted-[(l,3,4-thiadiazolyl) or (l,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
JP5273038B2 (en) 2006-05-08 2013-08-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Monocyclic heteroaryl compound
WO2007135626A2 (en) 2006-05-18 2007-11-29 Nxp B.V. Method of video coding
WO2012089106A1 (en) * 2010-12-27 2012-07-05 Sun Shuping Aromatic alkyne derivative as protein kinase inhibitor and medical use thereof
CN102584830A (en) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 Dihydroindene amide compounds, and medicinal composition and application thereof
GB2522226A (en) 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
CN110291086B (en) 2016-12-15 2023-08-11 阿瑞雅德制药公司 Aminothiazole compounds as C-KIT inhibitors
EP4274830A1 (en) 2021-01-06 2023-11-15 Theseus Pharmaceuticals, Inc. Aminothiazole compounds as c-kit inhibitors

Also Published As

Publication number Publication date
CN117050032A (en) 2023-11-14
IL267262A (en) 2019-08-29
AU2017376624B2 (en) 2021-11-11
US20220033392A1 (en) 2022-02-03
JP2020503297A (en) 2020-01-30
WO2018112136A1 (en) 2018-06-21
IL291099A (en) 2022-05-01
CN117105922A (en) 2023-11-24
AU2017376624A1 (en) 2019-07-04
KR102594476B1 (en) 2023-10-27
EA201991198A1 (en) 2020-01-13
JP2022185107A (en) 2022-12-13
US11001580B2 (en) 2021-05-11
BR112019012239A2 (en) 2019-11-05
JP7158382B2 (en) 2022-10-21
MX2019007079A (en) 2019-10-15
MX2022002579A (en) 2022-03-22
IL267262B (en) 2022-04-01
KR20190091537A (en) 2019-08-06
US11753404B2 (en) 2023-09-12
CA3047106A1 (en) 2018-06-21
CN110291086B (en) 2023-08-11
US20190352298A1 (en) 2019-11-21
AU2022200741A1 (en) 2022-02-24
AU2022200741B2 (en) 2024-03-07
CN110291086A (en) 2019-09-27
EP3555090A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
MA51878A (en) AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
MA53150A (en) BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS
MA55194A (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
MA42990A (en) COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA43169A (en) HETEROCYCLIC COMPOUNDS USED AS PI3K-GAMMA INHIBITORS
MA46091A (en) BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA40587A (en) AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS
MA48994A (en) ISOQUINOLEINS USED AS HPK1 INHIBITORS
MA51438A (en) HETEROCYCLIC COMPOUNDS USED AS LSD1 INHIBITORS
MA47123A (en) BENZOOXAZOLE DERIVATIVES AS MMUNOMODULATORS
MA45377A (en) HETEROCYCLIC COMPOUNDS AS ANTIBACTERIAL AGENTS
MA52063A (en) N - ((HET) ARYLMETHYL) HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMATIC KALLICREIN INHIBITORS
MA47576A (en) BICYCLIC OGA INHIBITOR COMPOUNDS
MA47013A (en) BENZOLACTAM COMPOUNDS USED AS KINASE PROTEIN INHIBITORS
MA41551A (en) BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MA47099A (en) BICYCLIC HETEROAROMATIC COMPOUNDS USED AS IMMUNOMODULATORS
MA45116A (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
MA45244A (en) SUBSTITUTED PYRIDINES USED AS DNMT1 INHIBITORS
MA40774A (en) DIARYLEUREA DERIVATIVES AS KINASE P38 INHIBITORS
MA40943A (en) SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA42919A (en) BICYCLIC COMPOUNDS USED AS ATX INHIBITORS
MA42918A (en) BICYCLIC COMPOUNDS USED AS ATX INHIBITORS
MA40940A (en) SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
MA54567A (en) PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
MA43862A (en) SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS